Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Randomized, Three-arm Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates in Healthy Adult Participants

Next Previous
X
Search
Trial Profile

An Open-label, Randomized, Three-arm Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates in Healthy Adult Participants

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALX-001 (Primary) ; Caffeine; Dextromethorphan; Midazolam
  • Indications Alzheimer's disease; Parkinson's disease
  • Focus Pharmacokinetics
  • Sponsors Allyx Therapeutics

    • Most Recent Events

    • 20 Nov 2024 Planned primary completion date changed from 1 Mar 2025 to 1 Jan 2025.
    • 20 Nov 2024 Status changed from not yet recruiting to active, no longer recruiting.
    • 15 Oct 2024 According to an Allyx Therapeutics meida release, company has been awarded a $3.3 million grant from the National Institutes of Health as part of its Small Business Innovation Research Commercial Readiness Pilot program. This funding will support further investigation ALX-001 and company intends to utilize this Commercial Readiness Pilot funding to support Phase I clinical pharmacokinetic drug-drug interaction study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top